Physician profile
James B Hackett
NPI 1285015503
$6,529.65
in general payments reported to CMS, 2019-2025
25 companies · $1,431 in 2025
The $1,431 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $316 · 2022: $622 · 2023: $2,658 · 2024: $1,503 · 2025: $1,431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,685 · Travel and Lodging: $827 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,684.93 |
| Travel and Lodging | $827.24 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,725.64 | 2022-2025 | Lux-Dx Insertable Cardiac Monitor, General - Therapies, Latitude Communicator Power Supply |
| Novartis Pharmaceuticals Corporation | $757.63 | 2023-2025 | |
| Abbott Laboratories | $561.02 | 2022-2025 | Durata, Fortify Assura, Assurity |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $524.57 | 2021-2025 | Lifevest |
| Biosense Webster, INC. | $455.42 | 2023-2025 | Carto 3 |
| Actelion Pharmaceuticals US, INC. | $173.51 | 2023-2024 | Opsumit, Uptravi |
| E.R. Squibb & Sons, L.L.C. | $171.23 | 2021-2025 | Camzyos, Eliquis |
| Pfizer INC. | $161.58 | 2022-2025 | |
| Kestra Medical Technology Services, INC. | $154.09 | 2022-2025 | Assure Wcd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.66 | 2024-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $106.65 | 2023-2025 | Farxiga |
| Kiniksa Pharmaceuticals, LTD. | $74.12 | 2022-2023 | Arcalyst |
| Edwards Lifesciences Corporation | $71.58 | 2022-2025 | Pascal |
| Novo Nordisk INC | $70.81 | 2024-2025 | Ozempic, Wegovy |
| Lexicon Pharmaceuticals, INC. | $67.03 | 2023-2024 | Inpefa |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Welch Allyn | $66.07 | 2021 | |
| Merck Sharp & Dohme LLC | $53.60 | 2024-2025 | Verquvo |
| Lilly USA, LLC | $47.63 | 2021 | |
| Janssen Pharmaceuticals, INC | $46.63 | 2023 | Xarelto |
| Kiniksa Pharmaceuticals International, Plc | $33.33 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $30.54 | 2025 | |
| Daiichi Sankyo INC. | $23.37 | 2023 | Injectafer |
| Impulse Dynamics (USA) INC. | $17.55 | 2023 | Optimizer |
| Alnylam Pharmaceuticals INC. | $16.58 | 2025 | Amvuttra |
| Chiesi USA, INC. | $12.81 | 2023 | Kengreal, Cleviprex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hackett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.